Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Lymphohistiocytosis, Hemophagocytic 1

Interventions

nilotinib 6bosutinib 4asciminib 3Imatinib Mesylate 3Decitabine 3decitabine and cedazuridine drug combination 2cedazuridine 2avapritinib 2Dasatinib 2Cytarabine 2Azacitidine 2treosulfan 1trametinib 1tagraxofusp 1pemigatinib 1olutasidenib 1luspatercept 1ivosidenib 1imetelstat 1glasdegib 1enasidenib 1dabrafenib 1GRN163L peptide 1Emapalumab 1Daunorubicin 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Emapalumab × Myeloid × Clear all
NCT01818492 2023-02-21

Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis

Swedish Orphan Biovitrum

Phase 2/3 Completed
45 enrolled 20 charts 1 FDA
Myeloid

Lymphohistiocytosis, Hemophagocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡